Novel players in cardioprotection Insulin like growth factor-1, angiotensin-(1–7) and angiotensin-(1–9)》.pdfVIP

G Model YPHRS-2861; No. of Pages 15 ARTICLE IN PRESS Pharmacological Research xxx (2015) xxx–xxx Contents lists available at ScienceDirect Pharmacological Research j o u rn al h omepage: w w w. elsev /locate/yphrs Review Novel players in cardioprotection: Insulin like growth factor-1, angiotensin-(1–7) and angiotensin-(1–9) Francisco Westermeier a , Mario Bustamante a , Mario Pavez a , Lorena García a , Mario Chiong a , María Paz Ocaranza b,c , Sergio Lavandero a,d,∗ a Advanced Centerfor Chronic Diseases (ACCDiS), Facultad Ciencias Químicas y Farmacéuticas Facultad de Medicina, Universidad de Chile, Santiago, Chile b Advanced Centerfor Chronic Diseases (ACCDiS), Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile c División de Enfermedades Cardiovasculares, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile d Departments of Internal Medicine (Division of Cardiology) and Molecular Biology, University of Texas Southwestern Medical Center, Dallas, TX, USA a r t i c l e i n f o a b s t r a c t Article history: Insulin-like growth factor-1, angiotensin-(1–7) and angiotensin-(1–9) have been proposed to be impor- Received 23 June 2015 tant mediators in cardioprotection. A large body of evidence indicates that insulin like growth factor-1 Received in revised form 27 June 2015 has pleotropic actions in the heart (i.e., contractility, metabolism, hypertrophy, autophagy, senescence Accepted 28 June 2015